NCT02203864View on ClinicalTrials.gov

Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 31, 1998

Primary Completion Date

February 28, 2001

Conditions
Melanoma
Interventions
BIOLOGICAL

BIBW2 component A

BIBW2 without IL-2 secreting cell line

BIOLOGICAL

BIBW2 component B

BIBW2 with IL-2 secreting cell line

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02203864 - Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma | Biotech Hunter | Biotech Hunter